摘要
[目的]探讨肺癌患者血清神经元烯醇化酶(NSE)的临床价值。[方法]采用放射免疫法检测374例肺癌患者、161例肺良性病变和158例正常对照组的血清NSE水平。[结果]肺癌患者血清NSE水平显著性高于肺癌良性疾病患者和正常对照组(P<0.01),小细胞肺癌血清NSE水平为最高。NSE水平随分期升高而增高,Ⅳ/Ⅲ期病人NSE水平显著高于Ⅰ/Ⅱ期病人(P<0.01)。NSE水平低的病人预后相对较好。[结论]NSE可作为一种有效的肺癌肿瘤标志物。
[Purpose] To investigate the clinical value of serum neuron specific enolase （NSE） in lung cancer. [Methods] The serum level of NSE in 374 cases with lung cancer, 161 cases with benign pulmonary disease and 158 healthy controls was detected by radioimmunoassay. [Results ] The serum NSE in patients with lung cancer was significantly higher than that in patients with benign lung disease and healthy controls （P〈0.01）. The serum NSE level in small-cell lung cancer was the highest, and increased with staging increase in the lung cancer. The serum NSE level in stage Ⅳ/Ⅲ was significantly higher than that in stage Ⅰ/Ⅱ （P〈0.01）. The prognosis in patients with low level NSE was superior to those with high level NSE. [Conclusions ] NSE may be used as a useful tumor marker in patients with lung cancer.
出处
《中国肿瘤》
CAS
2007年第8期631-632,共2页
China Cancer
